논문번호 | 243 | ||
논문제목(영문) | ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents. | ||
국내외구분 | 국외 | SCI여부 | SCI(E) |
연구책임자역할 | 공저자 | ||
주저자명 | Kim YH | ||
교신저자명 | Jang Y | ||
공동저자명 | Her AY, Jeong MH, Kim BK, Hong SJ, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, | ||
게제년월일 | 2020-02-01 | ||
ISSN | 0003-3197 | ||
Impact Factor | 2.255 | ||
학술지명 | ANGIOLOGY | ||
서지사항 | 0집 / 71권 / 2호, 페이지(139 - 149) | ||
요약초록문 (Abstract) 입력 |
The relative superiority of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on long-term clinical outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) with preserved left ventricular systolic function in the era of new generation drug-eluting stents is not well established. A total of 6436 patients with NSTEMI (ACEIs group: n = 3965 vs ARBs group: n = 2471) were enrolled. The major clinical end point was the occurrences of major adverse cardiac events (MACEs), defined as all-cause death, recurrent myocardial infarction (re-MI), and any repeat revascularization. After propensity score matching analysis, the cumulative incidences of MACEs (hazard ratio, 1.334; 95% confidence interval, 1.045-1.703; P = .021), any repeat revascularization, and target vessel revascularization (TVR) in the ARB group were significantly higher than that in the ACEI group. However, the cumulative incidences of all-cause death, cardiac death, re-MI, target lesion revascularization, and non-TVR were similar between the 2 groups. Hence, although the mortality and re-MI reduction benefits were similar between the 2 groups, the ACEIs group showed more prominent ability to decrease the occurrences of MACEs, any repeat revascularization, and TVR compared to the ARBs group in these patients during a 2-year follow-up period. | ||
파일 |
C243. ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents..pdf (648.0K) DATE : 2021-06-10 08:58:47 |
전라남도 장성군 남면 삼태리 산 109 나노바이오연구원 3층 306호 TEL : 061-392-6243 Fax: 061-392-6243
Copyright ⓒ 2014 Korea Cardiovascular Stent Research Institute. All right Reserved